Nonalcoholic Steatohepatitis (NASH) Diagnostics Market Size & Share, by Type (Serums Biomarkers, Hepatic Fibrosis Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers), End-user (Pharma & CRO, Hospitals, Academic Research Institutes) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 4718
  • Published Date: Mar 06, 2023
  • Report Format: PDF, PPT
  1. Market Definition
    1. Definition
    2. Market Segmentation
    3. Product Overview
  2. Assumptions and Acronyms
  3. Research Methodology
    1. Research Process
    2. Primary Research
    3. Secondary Research
  4. Executive Summary – Global Nonalcoholic Steatohepatitis (NASH) Diagnostics Market
  5. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  6. Decarbonization Strategy and Carbon Credit Benefit for Market Players
  7. Regulatory and Standards Landscape
  8. Industry Risk Analysis
  9. Global Economic Outlook: Challenges for Global Recovery and its Impact on Global Nonalcoholic Steatohepatitis (NASH) Diagnostics Market
  10. Technology Advancement in Nonalcoholic Steatohepatitis (NASH) Diagnostics Market
  11. Industry Supply Chain Analysis
  12. Analysis on Diagnostic Models
  13. Analysis on Recent Development or Trends
  14. Analysis on Types of Imaging Biomarkers
  15. Global Nonalcoholic Steatohepatitis (NASH) Diagnostics Market 2022-2033
    1. Market Overview
    2. By Value (USD Million)
    3. Market Segmentation Analysis 2022-2033
      1. By Type
        1. Serums Biomarkers, 2022-2033F (USD Million)
        2. Hepatic Fibrosis Biomarkers, 2022-2033F (USD Million)
        3. Oxidative Stress Biomarkers, 2022-2033F (USD Million)
        4. Apoptosis Biomarkers, 2022-2033F (USD Million)
        5. Others, 2022-2033F (USD Million)
      2. By End User
        1. Pharma & CRO Industry, 2022-2033F (USD Million)
        2. Hospitals, 2022-2033 (USD Million)
        3. Academic Research Institutes, 2022-2033F (USD Million)
        4. Others, 2022-2033 (USD Million)
      3. By Region
        1. North America, 2022-2033 (USD Million)
        2. Europe, 2022-2033 (USD Million)
        3. Asia Pacific, 2022-2033 (USD Million)
        4. Latin America, 2022-2033 (USD Million)
        5. Middle East & Africa, 2022-2033 (USD Million)
  16. North America Nonalcoholic Steatohepatitis (NASH) Diagnostics Market 2022-2033
    1. Market Overview
    2. By Value (USD Million)
    3. Market Segmentation Analysis 2022-2033
      1. By Type
        1. Serums Biomarkers, 2022-2033F (USD Million)
        2. Hepatic Fibrosis Biomarkers, 2022-2033F (USD Million)
        3. Oxidative Stress Biomarkers, 2022-2033F (USD Million)
        4. Apoptosis Biomarkers, 2022-2033F (USD Million)
        5. Others, 2022-2033F (USD Million)
      2. By End User
        1. Pharma & CRO Industry, 2022-2033F (USD Million)
        2. Hospitals, 2022-2033 (USD Million)
        3. Academic Research Institutes, 2022-2033F (USD Million)
        4. Others, 2022-2033 (USD Million)
      3. By Country
        1. US, 2022-2033F (USD Million)
        2. Canada, 2022-2033 (USD Million)
  17. Europe Nonalcoholic Steatohepatitis (NASH) Diagnostics Market 2022-2033
    1. Market Overview
    2. By Value (USD Million)
    3. Market Segmentation Analysis 2022-2033
      1. By Type
      2. By End User
      3. By Country
        1. UK, 2022-2033F (USD Million)
        2. Germany, 2022-2033 (USD Million)
        3. Italy, 2022-2033F (USD Million)
        4. France, 2022-2033 (USD Million)
        5. Spain, 2022-2033F (USD Million)
        6. Russia, 2022-2033 (USD Million)
        7. Netherlands, 2022-2033F (USD Million)
  18. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Diagnostics Market 2022-2033
    1. Market Overview
    2. By Value (USD Million)
    3. Market Segmentation Analysis 2022-2033
      1. By Type
      2. By End User
      3. By Country
        1. China, 2022-2033F (USD Million)
        2. India, 2022-2033 (USD Million)
        3. Japan, 2022-2033F (USD Million)
        4. Australia, 2022-2033 (USD Million)
        5. South Korea, 2022-2033F (USD Million)
        6. Singapore, 2022-2033 (USD Million)
        7. Rest of Asia Pacific, 2022-2033 (USD Million)
  19. Latin America Nonalcoholic Steatohepatitis (NASH) Diagnostics Market 2022-2033
    1. Market Overview
    2. By Value (USD Million)
    3. Market Segmentation Analysis 2022-2033
      1. By Type
      2. By End User
      3. By Country
        1. Brazil, 2022-2033F (USD Million)
        2. Argentina, 2022-2033 (USD Million)
        3. Mexico, 2022-2033F (USD Million)
        4. Rest of Latin America, 2022-2033 (USD Million)
  20. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Diagnostics Market 2022-2033
    1. Market Overview
    2. By Value (USD Million)
    3. Market Segmentation Analysis 2022-2033
      1. By Type
      2. By End User
      3. By Country
        1. GCC, 2022-2033F (USD Million)
        2. Israel, 2022-2033 (USD Million)
        3. South Africa, 2022-2033F (USD Million)
        4. Rest of the Middle East and Africa, 2022-2033 (USD Million)
  21. Competitive Landscape
    1. Company Market Share Analysis
    2. Company Profiles
      1. Echosens
      2. Prometheus Laboratories
      3. Genfit
      4. Siemens Medical Solutions USA, Inc.
      5. BioPredictive
      6. Quest Diagnostics Incorporated.
      7. Meridian Bioscience, Inc.
      8. Laboratory Corporation of America Holdings
      9. Bristol-Myers Squibb Company
      10. One Way Liver SL
      11. Other Major Players
    3. End User Analysis

Companies Dominating the Nonalcoholic Steatohepatitis Diagnostics Landscape

top-features-companies
    • Echosen
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Prometheus Laboratories
    • Genfit
    • Siemens Medical Solutions USA, Inc.
    • BioPredictive
    • Quest Diagnostics Incorporated.
    • Meridian Bioscience, Inc.
    • Laboratory Corporation of America Holdings
    • Bristol-Myers Squibb Company
    • One Way Liver SL

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Echosens and Novo Nordisk A/S announced a partnership to advance the early diagnosis of NASH and increase awareness of the disease. They have collaborated to support additional clinical validation, the generation of real-world evidence, and the adoption of non-invasive diagnostic tests for NASH. They decided to collaborate for raising awareness of the condition and the value of early diagnosis and treatment. By 2025, the companies hope to double the rate of advanced-stage to severe NASH diagnoses.

  • GENFIT company announced the launch of the NASHnext, a novel, non-invasive diagnostic test for nonalcoholic steatohepatitis (NASH). The test is offered exclusively in the U.S. and Canada through Labcorp, a leading global life sciences company. NASHnext, GENFIT's proprietary diagnostic technology, is powered by NIS4 and was described in The Lancet Gastroenterology and Hepatology as using a novel blood-based molecular biomarker test to detect NASH and significant fibrosis, also known as at-risk NASH, in patients with at least one metabolic risk factor.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4718
  • Published Date: Mar 06, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing prevalence of NASH and NAFLD and rising demand for providing novel diagnostic tools are the major factors driving the market growth.

The market is anticipated to attain CAGR of 23.8% over the forecast period, i.e., 2023-2033.

Stringent regulations for biomarkers approval by regulatory bodies and absence of NAFLD/NASH from health policies focused on obesity are estimated to be the growth hindering factors for the market expansion.

The market in the North America region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Echosens, Prometheus Laboratories, GENFIT SA, Siemens Medical Solutions USA, Inc., BioPredictive S.A.S, ONE WAY LIVER, SL, and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, end user, and by region.

The serum biomarkers segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying